Lenox Wealth Management’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Lenox Wealth Management’s Portfolio OPNT Stock Details OPNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$0	Buy	+40	New	+$415	﹤0.01%	812

Other funds holding OPNT

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fondren Management Houston, Texas $16.9M AUM 5.82% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

PCM

Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MFIM

Mesirow Financial Investment Management Chicago, Illinois $6.18B AUM 18.43% 1-Year Est. Return

AIM

Alambic Investment Management Belvedere, California $9.12M AUM 34.54% 1-Year Est. Return

Lenox Wealth Management's OPNT Position: Q2 2020 in Review

Lenox Wealth Management opened a new position in Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q2 2020: 40 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #812 among its holdings.

30 funds tracked by Wall St. Rank hold OPNT as of Q2 2020.

Lenox Wealth Management held 40 shares of Opiant Pharmaceuticals, Inc. Common Stock worth $0 as of Q2 2020.
Opiant Pharmaceuticals, Inc. Common Stock was a new Lenox Wealth Management position in Q2 2020.
Opiant Pharmaceuticals, Inc. Common Stock made up ﹤0.01% of Lenox Wealth Management's portfolio in Q2 2020, its #812 holding.
30 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Lenox Wealth Management's 13F filing for Q2 2020, filed 28 Jul 2020.